A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

BACKGROUND: Activation of the vascular endothelial growth factor receptor (VEGFR) and the oncogenic Src pathway has been implicated in the development of castration-resistant prostate cancer (CRPC) in preclinical models. Cediranib and dasatinib are multi-kinase inhibitors targeting VEGFR and Src res...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Spreafico, Anna, Chi, Kim N., Sridhar, Srikala S., Smith, David C., Carducci, Michael A., Kavsak, Peter, Wong, Tracy S., Wang, Lisa, Ivy, S. Percy, Mukherjee, Som Dave, Kollmannsberger, Christian K., Sukhai, Mahadeo A., Takebe, Naoko, Kamel-Reid, Suzanne, Siu, Lillian L., Hotte, Sebastien J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4281773/
https://ncbi.nlm.nih.gov/pubmed/24788563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0106-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados